Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer

por Feliu, J, Barriuso, J
Publicado 2011

Severe toxicity caused by sorafenib in hepatocellular carcinoma match the data from renal cell carcinoma

por Lamarca, A, Feliu, J, Barriuso, J
Publicado 2012

SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014

por Garcia-Carbonero, R., JImenez-Fonseca, P., Teulé, A., Barriuso, J., Sevilla, I.
Publicado 2014

Biomarker concordance between primary colorectal cancer and its metastases

por Bhullar, D.S., Barriuso, J., Mullamitha, S., Saunders, M.P., O'Dwyer, S.T., Aziz, O.
Publicado 2019

Defining a role for systemic chemotherapy in local and advanced appendix adenocarcinoma

por Strach, M.C., Chakrabarty, B., Nagaraju, R.T., Mullamitha, S., Braun, M., O’Dwyer, S.T., Aziz, O., Barriuso, J.
Publicado 2023

A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cance...

por Kang, Y-K, Rha, S Y, Tassone, P, Barriuso, J, Yu, R, Szado, T, Garg, A, Bang, Y-J
Publicado 2014

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

por Postel-Vinay, S, Arkenau, H-T, Olmos, D, Ang, J, Barriuso, J, Ashley, S, Banerji, U, De-Bono, J, Judson, I, Kaye, S
Publicado 2009

A novel, highly efficient β-glucosidase with a cellulose-binding domain: characterization and properties of native and recombinant proteins

por Méndez-Líter, J. A., Gil-Muñoz, J., Nieto-Domínguez, M., Barriuso, J., de Eugenio, L. I., Martínez, M. J.
Publicado 2017

SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018)

por González-Flores, E., Serrano, R., Sevilla, I., Viúdez, A., Barriuso, J., Benavent, M., Capdevila, J., Jimenez-Fonseca, P., López, C., Garcia-Carbonero, R.
Publicado 2018

Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO tria...

por Rivera, Fernando, Romero, C., Jimenez-Fonseca, P., Izquierdo-Manuel, M., Salud, A., Martínez, E., Jorge, M., Arrazubi, V., Méndez, J. C., García-Alfonso, P., Reboredo, M., Barriuso, J., Muñoz-Unceta, N., Jimeno, R., López, C.
Publicado 2019

Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric can...

por Rivera, Fernando, Romero, C., Jimenez-Fonseca, P., Izquierdo-Manuel, M., Salud, A., Martínez, E., Jorge, M., Arrazubi, V., Méndez, J. C., García-Alfonso, P., Reboredo, M., Barriuso, J., Muñoz-Unceta, N., Jimeno, R., López, C.
Publicado 2019

Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours

por Kaye, S, Aamdal, S, Jones, R, Freyer, G, Pujade-Lauraine, E, de Vries, E G E, Barriuso, J, Sandhu, S, Tan, D S-W, Hartog, V, Kuenen, B, Ruijter, R, Kristensen, G B, Nyakas, M, Barrett, S, Burke, W, Pietersma, D, Stuart, M, Emeribe, U, Boven, E
Publicado 2012

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

por Gyawali, B., de Vries, E.G.E., Dafni, U., Amaral, T., Barriuso, J., Bogaerts, J., Calles, A., Curigliano, G., Gomez-Roca, C., Kiesewetter, B., Oosting, S., Passaro, A., Pentheroudakis, G., Piccart, M., Roitberg, F., Tabernero, J., Tarazona, N., Trapani, D., Wester, R., Zarkavelis, G., Zielinski, C., Zygoura, P., Cherny, N.I.
Publicado 2021